Assess Response to Therapy

Changes in Vectra DA scores provide quantitative insight to help assess your patients’ responses to therapy.

Vectra DA has assessed rheumatoid arthritis disease activity in response to many currently available therapeutic options, including:

  • Methotrexate ± corticosteroids1,2,3
  • Biologic therapy (abatacept, adalimumab, etanercept, golimumab, infliximab and tocilizumab*4-8)
  • Tofacitinib9
* Change in Vectra DA score during tocilizumab treatment may underestimate the change in clinical response.7,8 For more information on this topic please visit Frequently Asked Questions. 

 

Vectra DA algorithm scores differed significantly between EULAR response categories in anti-TNF-treated patients.5

vectra-da-algorithm

Pg8_StudyDesign

 

The value of obtaining a baseline Vectra DA score

 


References:

* 1. Hambardzumyan K, Bolce R, Saevarsdottir S, et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial [published online ahead of print May 8, 2014]. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204986.

* 2. Li W, Hensvold AH, Saevarsdottir S, et al. Characterization of the multi-biomarker disease activity (Vectra® DA algorithm) score in a subgroup of patients from the Epidemiological Investigation of Rheumatoid Arthritis (EIRA) cohort receiving methotrexate. Poster presented at: EULAR Annual Congress of Rheumatology; June 12-15, 2013; Madrid, Spain. Poster SAT0033.

* 3. Bakker MF, Cavet G, Jacobs JWG, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis. 2012. doi:10.1136/annrheumdis-2011-200963.

* 4. Haney DJ, Cavet G, Durez P, et al. Correlation of a multi-biomarker disease activity response assessment to disease activity score 28 (c-reactive protein) response assessment and Omeract Ramris scores in a placebo-controlled rheumatoid arthritis clinical trial with abatacept (ASSET). Arthritis Rheum. 2012;64(suppl 10):2159

* 5. Hirata S, Li W, Defranoux N, et al. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: a retrospective observational study [published online ahead of print October 8, 2014]. Mod Rheumatol. doi:10.3109/14397595.2014.958893.

* 6. Lamberth S, Cherkas Y, Brodmerkel C, et al. Utility of Vectra-DA on assessment of rheumatoid arthritis disease activity and golimumab response: results of a pilot study from a phase 3 trial in patients with active rheumatoid arthritis despite methotrexate therapy. Arthritis Rheum. 2012;64(suppl 10):2165.

* 7. Reiss WG, Devenport JN, Low JM, et al. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis. Rheumatology International. 2015 DOI:10.1007/s00296-015-3285-2

* 8. Hanami K, Hirata S, Tasaka H, et al. Behavior of the multi-biomarker disease activity (Vectra® DA algorithm) score and components in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis. 2013;72(suppl 3):391.

* 9. Yamaoka K, Kubo S, Li W, et al. Effects of tofacitinib treatment on leptin and other components of the multi-biomarker disease activity score in patients with rheumatoid arthritis. Ann Rheum Dis. 2014;73(suppl 2).